Compare AIRE & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | LEXX |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | Canada |
| Employees | N/A | 7 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 16.2M |
| IPO Year | 2023 | N/A |
| Metric | AIRE | LEXX |
|---|---|---|
| Price | $0.32 | $0.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $2.00 | $1.50 |
| AVG Volume (30 Days) | ★ 1.2M | 132.5K |
| Earning Date | 06-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,518,498.00 | N/A |
| Revenue This Year | $191.53 | N/A |
| Revenue Next Year | $44.80 | $601.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 376.42 | N/A |
| 52 Week Low | $0.14 | $0.46 |
| 52 Week High | $1.55 | $1.90 |
| Indicator | AIRE | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 52.27 |
| Support Level | $0.28 | $0.58 |
| Resistance Level | $0.35 | $0.87 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 53.47 | 44.30 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.